"Myelodysplastick\u00FD syndrom (MDS) je klon\u00E1ln\u00ED onemocn\u011Bn\u00ED hemopoetick\u00E9 tk\u00E1n\u011B. Zahrnuje heterogenn\u00ED skupinu onemocn\u011Bn\u00ED, pro n\u011B\u017E je charakteristick\u00FD nepom\u011Br mezi bohatou krvetvorbou a perifern\u00ED pancytopeni\u00ED jako n\u00E1sledek inefektivn\u00ED hemopoezy s klinick\u00FDmi projevy anemie, infekce a krv\u00E1cen\u00EDm. Mo\u017En\u00E1 je transformace do akutn\u00ED leukemie. Podle klasifikace FAB (French-American-British) se MDS d\u011Bl\u00ED do 5 podskupin, nov\u011Bji podle klasifikace WHO do 8 skupin (tabulka 1).1,2 Celou skupinu je\u0161t\u011B vzhledem k terapeutick\u00FDm intervenc\u00EDm d\u011Bl\u00EDme na vysoce a n\u00EDzce rizikov\u00E9 MDS s pou\u017Eit\u00EDm mezin\u00E1rodn\u00EDho prognostick\u00E9ho sk\u00F3rovac\u00EDho syst\u00E9mu IPSS (International Prognostic Scoring System), nov\u011Bji WPSS (WHO-based prognostic scoring system) (tabulka 2 a 4)." . . . "[D7DA3D9AF930]" . . "7"^^ . "myelodysplastic syndrome; therapy approaches; epigenetic; immunomodulation; chelatation"@en . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k terapii myelodysplastick\u00E9ho syndromu" . "Myelodysplastick\u00FD syndrom (MDS) je klon\u00E1ln\u00ED onemocn\u011Bn\u00ED hemopoetick\u00E9 tk\u00E1n\u011B. Zahrnuje heterogenn\u00ED skupinu onemocn\u011Bn\u00ED, pro n\u011B\u017E je charakteristick\u00FD nepom\u011Br mezi bohatou krvetvorbou a perifern\u00ED pancytopeni\u00ED jako n\u00E1sledek inefektivn\u00ED hemopoezy s klinick\u00FDmi projevy anemie, infekce a krv\u00E1cen\u00EDm. Mo\u017En\u00E1 je transformace do akutn\u00ED leukemie. Podle klasifikace FAB (French-American-British) se MDS d\u011Bl\u00ED do 5 podskupin, nov\u011Bji podle klasifikace WHO do 8 skupin (tabulka 1).1,2 Celou skupinu je\u0161t\u011B vzhledem k terapeutick\u00FDm intervenc\u00EDm d\u011Bl\u00EDme na vysoce a n\u00EDzce rizikov\u00E9 MDS s pou\u017Eit\u00EDm mezin\u00E1rodn\u00EDho prognostick\u00E9ho sk\u00F3rovac\u00EDho syst\u00E9mu IPSS (International Prognostic Scoring System), nov\u011Bji WPSS (WHO-based prognostic scoring system) (tabulka 2 a 4)."@cs . . . "RIV/00064165:_____/09:5852!RIV10-MZ0-00064165" . . "2" . "N" . "Current therapeutic approaches in myelodysplastic sydrome"@en . . "RIV/00064165:_____/09:5852" . . . "1801-1209" . . . "CZ - \u010Cesk\u00E1 republika" . . "Jon\u00E1\u0161ov\u00E1, Anna" . "2009" . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k terapii myelodysplastick\u00E9ho syndromu"@cs . "Current therapeutic approaches in myelodysplastic sydrome"@en . "1"^^ . "Farmakoterapie" . . "342524" . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k terapii myelodysplastick\u00E9ho syndromu"@cs . . . "Myelodysplastic syndrome (MDS) is clonal disease of hemopoietic tissue. It includes heterogeneous group of diseases with characteristics discrepancy between cellular bone marrow and peripheral pancytopenia and risk od transformation to acute leukemia. Using to FAB classification MDS id divided into 5 subgroups and according to recently developed WHO classification into 8 groups. The whole entity is divided into low and high risk MDS using IPSS (International prognostic scoring system) and newly WPSS (WHO-based prognostic scoring system)."@en . . "Sou\u010Dasn\u00E9 p\u0159\u00EDstupy k terapii myelodysplastick\u00E9ho syndromu" . "1"^^ .